MRKS-Brand-Logo-Final-FullColor.png
Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid
05 sept. 2024 06h30 HE | Merakris Therapeutics
Part 2 of the Phase II multicenter clinical study for the investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid, will begin late 2024.
merakris_logo_4color copy.jpg
Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical Trial
05 déc. 2023 06h30 HE | Merakris Therapeutics
Merakris Therapeutics announces it has fully enrolled the first part of a clinical trial to evaluate its investigational drug product, Dermacyte® Liquid.
merakris_logo_4color copy.jpg
Wound Healing Technology Company Merakris Adds Two Executives to Leadership Team
15 août 2023 06h30 HE | Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Merakris Therapeutics has added two new executives to its leadership team as it prepares to expand its product line and increase its...
merakris_logo_4color copy.jpg
Merakris Sponsored Study Opens Door to Precision-Based Approaches to Wound Healing
13 sept. 2022 06h00 HE | Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2022 (GLOBE NEWSWIRE) -- A recently published manuscript containing research sponsored, in part, by Merakris Therapeutics has opened the door to more...
merakris_logo_4color copy.jpg
Study Shows Effectiveness of Merakris’ Wound Care Products
02 juin 2022 07h30 HE | Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 02, 2022 (GLOBE NEWSWIRE) -- A peer-reviewed case study in the May 21 edition of SAGE Open Medical Case Reports highlights the effectiveness of two Merakris...